A Florida woman has filed a Xarelto lawsuit on behalf of her late husband, who allegedly died as a result of internal bleeding-related injuries.
According to court documents, the case was filed on June 23rd in the U.S, District Court, Southern District of Florida, and blames Johnson & Johnson and Bayer Healthcare for injuries allegedly caused by the blood thinner. The companies, who jointly market Xarelto, failed to adequately warn about its potential to cause internal bleeding side effects that cannot be reversed, due to a lack of antidote, the plaintiff alleges. Internal bleeding side effects of warfarin, by comparison, can be reversed with the administration of Vitamin K.
According to claims, the plaintiff in this Xarelto lawsuit suffered a subdural hemorrhage in June 2012, after he started taking the medication in January 2012. When he was admitted to Pennsylvania’s Abington Memorial Hospital, doctors performed a right frontal bur hole with evacuation to curb the bleeding, but were unsuccessful. The man eventually bled to death on June 28, 2012.
Claims filed in this Xarelto lawsuit are similar to those included in several others already filed in the U.S. Since the drug garnered approval in 2011, plaintiffs have complained of cerebral and gastrointestinal hemorrhaging and other internal bleeding injuries caused by the medication. Xarelto belongs to a new class of blood thinners referred to as direct thrombin inhibitors, and has been marketed by its manufacturer as an alternative over warfarin, a decades-old blood thinner.
Xarelto has also been named in hundreds of adverse event reports recorded by the U.S. Food and Drug Administration (FDA). In the first quarter of 2013 alone, the Institute for Safe Medicine Practices (ISMP) issued a report revealing that 680 adverse event reports related to Xarelto use had been filed in the regulator’s database. The ISMP’s findings, which were released in May 2014, indicated that complaints of this drug advanced those of Pradaxa, another direct thrombin inhibitor. Elderly patients were also found to be 7.2% more likely to die of Xarelto internal bleeding than those being treated with warfarin, who ran a 6.5% chance of death.
Patients suffering from Xarelto bleeding may be vomiting or coughing up blood, see blood in their urine, experience swelling or weakness in their extremities, and frequent bleeding from gums.